PROMIS NEUROSCIENCES (F:23J0) — Market Cap & Net Worth
Market Cap & Net Worth: PROMIS NEUROSCIENCES (23J0)
PROMIS NEUROSCIENCES (F:23J0) has a market capitalization of $576.86K (€493.42K) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #30496 globally and #2707 in its home market, demonstrating a 1849.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PROMIS NEUROSCIENCES's stock price €6.90 by its total outstanding shares 2152444 (2.15 Million).
PROMIS NEUROSCIENCES Market Cap History: 2017 to 2026
PROMIS NEUROSCIENCES's market capitalization history from 2017 to 2026. Data shows growth from $20.69 Million to $17.36 Million (1.38% CAGR).
PROMIS NEUROSCIENCES Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PROMIS NEUROSCIENCES's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 23J0 by Market Capitalization
Companies near PROMIS NEUROSCIENCES in the global market cap rankings as of May 4, 2026.
Key companies related to PROMIS NEUROSCIENCES by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PROMIS NEUROSCIENCES Historical Marketcap From 2017 to 2026
Between 2017 and today, PROMIS NEUROSCIENCES's market cap moved from $20.69 Million to $ 17.36 Million, with a yearly change of 1.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €17.36 Million | +2.99% |
| 2025 | €16.86 Million | +692.90% |
| 2024 | €2.13 Million | -15.08% |
| 2023 | €2.50 Million | -75.61% |
| 2022 | €10.27 Million | -14.79% |
| 2021 | €12.05 Million | +80.54% |
| 2020 | €6.67 Million | -63.17% |
| 2019 | €18.12 Million | -4.00% |
| 2018 | €18.87 Million | -8.76% |
| 2017 | €20.69 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of PROMIS NEUROSCIENCES was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $576.86K USD |
| MoneyControl | $576.86K USD |
| MarketWatch | $576.86K USD |
| marketcap.company | $576.86K USD |
| Reuters | $576.86K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PROMIS NEUROSCIENCES
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more